évaluation de la disponibilité et l’utilisation du sérum antivenimeux dans le district de Bamako, Mali, Afrique de l’Ouest

详细信息    查看全文

• 作者：B. S. I. Dramé (1) (2)
  M. Dabo (2)
  N. Diani (1)
  B. Cissé (3)
  
• 关键词：Morsure de serpent ; Envenimation ; Sérum antivenimeux ; Partenariat privé ; publique ; H?pital ; Bamako ; Mali ; Afrique intertropicale ; Snakebite ; Envenomation ; Antivenom ; Public ; private partnership ; Hospital ; Bamako ; Mali ; Sub ; Saharan Africa
• 刊名：Bulletin de la Soci茅t茅 de pathologie exotique
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：105
• 期：3
• 页码：179-183
• 全文大小：183KB
• 参考文献：1. Chippaux JP (1998) Snake-bites: appraisal of the global situation. Bull World Health Organ 76(5):515-24
  2. Chippaux JP (1999) L’envenimation ophidienne en Afrique: épidémiologie, clinique et traitement. Ann Inst Pasteur-Actualités 10:161-71 CrossRef
  3. Chippaux JP (2002) Venins de serpent et envenimations. IRD Editions, Paris
  4. Chippaux JP, Goyffon M (1991) La sérothérapie antivenimeuse: ses applications, ses limites, son avenir. Bull Soc Pathol Exot 84(3):286-97
  5. Dabo A, Diawara SI, Dicko A, et al (2002) évaluation des morsures de serpent et de leur traitement dans le village de Bancoumana au Mali. Bull Soc Pathol Exot 95(3):160-62 [ents/articles-bull/T95-3-Env8.pdf" class="a-plus-plus">http://www.pathexo.fr/documents/articles-bull/T95-3-Env8.pdf]
  6. Diffo JLD, Dzikouk G, LeBreton M, et al (2005) Distribution des sérums antivenimeux au Cameroun. Bull Soc Pathol Exot 98(4):302-03 [ents/articles-bull/T98-4-2752-11-2p.pdf" class="a-plus-plus">http://www.pathexo.fr/documents/articles-bull/T98-4-2752-11-2p.pdf]
  7. Dramé B, Diani N, Togo MM, et al (2005) Les accidents d’envenimation par morsure de serpent dans le service des urgences chirurgicales de l’h?pital Gabriel-Touré, Bamako, Mali. Bull Soc Pathol Exot 98(4):287-90 [ents/articles-bull/T98-4-2752-12-3p.pdf" class="a-plus-plus">http://www.pathexo.fr/documents/articles-bull/T98-4-2752-12-3p.pdf]
  8. Reid HA, Theakston RDG (1984) Les morsures de serpent. Bull World Health Organ 62(1):27-8
  
• 作者单位：B. S. I. Dramé (1) (2)
  M. Dabo (2)
  N. Diani (1)
  B. Cissé (3)
  
  1. CHU H?pital du Mali, Missabougou, Bamako, Mali
  2. CHU Gabriel-Touré, Bamako, Mali
  3. Faculté de médecine, de pharmacie et d’odontostomatologie (FMPOS), Bamako, Mali
  
• ISSN：1961-9049

文摘

The aim of this study is to describe the difficulties related to problems of supply and use of antivenom serum (SAV) in the district of Bamako. A retrospective study over a span of five years (January 1998–December 2002) and an interview with the staff of various facilities were conducted. The study included 2 wholesalers of pharmaceuticals, 20 private pharmacies, and 2 hospital pharmacies as they were involved in antivenom trades. A market-driving ability survey of driving practice was conducted in 37 community health centers (CHCs) and 4 dispensaries because they performed antivenom treatments during the study period. A total of 3,318 doses of antivenom were bought, including 84.4% by the People Pharmacy of Mali (PPM), a public organization, and 15.6% by Laborex, a private company. These were out of stock in 1999. Three kinds of SAV were ordered: the polyvalent IPSER Africa (1,200 vials or 36.2%), FAV Africa (318 vials or 9.6%), and Sii anti-snake venom polyvalent serum (1,800 vials or 54.2%). Orders from PPM involved IPSER Africa (Pasteur Mérieux Serum & Vaccines) and Sii anti-snake venom polyvalent serum (Serum Institute of India), and those from Laborex involved IPSER Africa and FAVAfrica (Aventis Pasteur). Onehalf of private pharmacies (54.3%) had made at least one order of SAV. The PPM lost 50% of 2,000 vials of SAV in 1996 due to the expiration of vials that were bought. Private pharmacies lost 3.6% of stocks due to expiration. Prices varied depending on the type of service and the point of sale. Costs of vials were 19,440-5,000 CFA francs (29.6-3.4 euros) for Sii antivenom and 50,200-3,000 CFA francs (76.5-6.1 euros) for FAV Africa antivenom. In CHCs, 59.5% of prescribers were unaware of the indications and methods of proper administration of the SAV, 32.3% ignored the existence of SAV, and 30.9% were skeptical about its effectiveness in treatment of envenomation by snakebite.